Indivior Pharmaceuticals, Inc 6-K, filed Feb 4, 2025
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2025-02-04
For: 2025-02-04
View Original
Added on
July 07, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on February 4, 2025.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of February 2025
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
No.
|
Description
of Exhibit
|
|
99.1
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: February 04,
2025
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
INDIVIOR PLC
SHARE REPURCHASE PROGRAM
WEEKLY REPORT
February 4, 2025
INDIVIOR PLC ("Indivior") announces that it purchased for
cancellation a total of 204,247 of its ordinary shares of $0.50
each through Morgan Stanley & Co. International Plc in the
period from January 27, 2025, up to and including January 31, 2025,
in connection with its $100m Share Repurchase Program. Aggregated
information on the purchase of these shares can be found in the
table below.
Following the purchase and cancellation of the above shares
(including those purchased but not yet settled), Indivior has
124,137,286 ordinary shares of $0.50 each with voting rights in
issue. There are no shares held in treasury.
The above figure (124,137,286) may be used by shareholders (and
others with notification obligations) as the denominator for the
calculation by which they will determine if they are required to
notify their interest in, or a change to their interest in,
Indivior under the FCA's Disclosure Guidance and Transparency
Rules.
All repurchases by Indivior are "On Exchange" transactions (as such
term is defined in the rules of the London Stock Exchange) and "on
market" for the purposes of the Companies Act 2006.
Aggregated information
|
Trading
Date
|
Trading
Venue
|
Aggregated
daily volume (number of shares)
|
Daily
weighted average purchase price of the shares (p)
|
|
27/01/2025
|
LSE
|
15,225
|
964.57
|
|
27/01/2025
|
BATE
|
5,912
|
963.95
|
|
27/01/2025
|
CHIX
|
18,321
|
965.68
|
|
27/01/2025
|
AQUIS
|
2,442
|
967.02
|
|
28/01/2025
|
LSE
|
20,092
|
982.38
|
|
28/01/2025
|
BATE
|
4,586
|
984.79
|
|
28/01/2025
|
CHIX
|
14,490
|
982.55
|
|
28/01/2025
|
AQUIS
|
2,330
|
985.06
|
|
29/01/2025
|
LSE
|
20,652
|
987.47
|
|
29/01/2025
|
BATE
|
3,602
|
990.21
|
|
29/01/2025
|
CHIX
|
15,514
|
988.73
|
|
29/01/2025
|
AQUIS
|
1,068
|
993.23
|
|
30/01/2025
|
LSE
|
14,877
|
982.26
|
|
30/01/2025
|
BATE
|
7,449
|
983.03
|
|
30/01/2025
|
CHIX
|
16,455
|
982.00
|
|
30/01/2025
|
AQUIS
|
1,734
|
980.91
|
|
31/01/2025
|
LSE
|
9,956
|
979.80
|
|
31/01/2025
|
BATE
|
6,684
|
979.75
|
|
31/01/2025
|
CHIX
|
19,365
|
976.14
|
|
31/01/2025
|
AQUIS
|
3,493
|
990.02
|
Transaction details
In accordance with Article 5(1)(b) of the assimilated Market Abuse
Regulation (EU) No 596/2014, as it forms part of Retained EU Law as
defined in the European Union (Withdrawal) Act 2018 and Commission
Delegated Regulation (EU) 2016/1052, a full breakdown of the
individual purchases of ordinary shares made by Morgan Stanley
& Co. International Plc on behalf of Indivior during the above
period as part of the Share Repurchase Program can be found
at www.indivior.com/en/investors/shareholder-information/share-repurchase-program.
Indivior PLC's Legal Entity Identifier code is
213800V3NCQTY7IED471.
Contact:
Jason Thompson
Vice President, Investor Relations
1-804-402-7123